spacer
home > epc > autumn 2008 > for the children
PUBLICATIONS
European Pharmaceutical Contractor

For the Children

Most drugs prescribed for children have not undergone a paediatric trial. Only 20 to 30 per cent of drugs approved by the Food and Drug Administration (FDA) are labelled for paediatric use, so by necessity doctors have routinely given drugs to children ‘off label’.

This means the drug hasn’t been studied in children in adequate, well-controlled clinical trials approved by the agency. If adequate investigations are not conducted to provide data for evidencebased treatment for paediatric patients, each patient essentially becomes an uncontrolled experiment. FDA believes it is crucial to paediatric public health for therapies that will be used in children to have evidence-based paediatric information in the labelling.

The historical lack of paediatric drug testing is due to a combination of factors. Ethical concerns such as patient selection, placebo use and consent/assent made many people uncomfortable with studying paediatric patients in clinical trials. Paediatric trials also require specialised research centres equipped and staffed to handle the paediatric population. In addition, sufficient numbers of paediatric patients with a given condition are often limited, and accumulating enough patients for a study may require many sites and a longer course of time.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Lisa L Mathis is a board certified paediatrician who works in the Office of New Drugs in the Center for Drug Evaluation and Research as the Associate Director for the Pediatric and Maternal Health Staff, FDA. The Pediatric and Maternal Health Staff works to provide clinicians and patients with information needed to appropriately use medications in children, and during pregnancy and lactation.
spacer
Lisa L Mathis
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Pharma Services Announces Organization Updates

Philadelphia, PA – May 20, 2019 – PCI Pharma Services, a leading biopharmaceutical outsourcing services provider, is pleased to announce the following management updates to help drive the company’s future vision, strategy and growth.
More info >>

White Papers

Modular Feeding Systems for Prefilled Syringes and Injection Devices

Dividella

The pre-filled syringe and injection device is an increasingly attractive presentation for both new and established parenteral pharmaceuticals. We will explore how innovative carton packaging solutions can enhance this presentation whilst meeting the stringent requirements of product protection.
More info >>

 
Industry Events

World Pharma Week 2019

17-20 June 2019, Seaport World Trade Center, Boston

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement